Deal or Case news
NautaDutilh advised Merus N.V., a clinical-stage oncology company, in raising approximately USD 460 million in gross proceeds through an upsized underwritten public offering of 8,682,500 common shares.

This offering included the underwriter's option to purchase an additional 1,132,500 common shares at a public offer price of USD 53.00 per share. All the shares in the offering were sold by Merus.

We are pleased to have assisted our longstanding client Merus in this significant transaction as they continue their journey to clinically advance targeted treatments to address unmet needs of patients with various types of cancer.
Paul van der Bijl, Corporate M&A partner

NautaDutilh's team advising on the transaction was led by Paul van der Bijl, supported by Sanne Mesu, Joppe Schoute, Mohamad Jabari, Nina Kielman and Nick Roovers. The team worked alongside the US team of Latham & Watkins.

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.